Compliance is at the forefront of pharma companies’ minds today.
Companies face the threat of staggering fines and increased scrutiny
from regulatory bodies. A growing level of public distrust of the
industry also carries a negative effect on companies’ reputations. These
events have created a new regulatory environment that has dramatically
affected companies’ organizational structures and practices. In fact,
the industry’s most influential companies have reexamined—and sometimes
reinvented—the way they do business.
This new landscape thrusts compliance groups into the center of the
action. Compliance teams have gained additional resources and a stronger
tie to executive leadership. But with this increased power comes
challenges in communicating regulatory changes, in training and testing
employees, and in ensuring compliance across an organization.
This report examines the current state of compliance management at
some of the pharmaceutical industry’s top companies. It looks at metrics
and strategies surrounding three aspects of compliance success:
- Structure, Headcounts and Investment – Provides up-to-date
structuring strategies, headcounts and investments of top compliance
groups
- Monitoring and Ensuring Compliance – Details companies’
strategies regarding monitoring, training, testing, documentation,
firewalls, and much more
- Activities and Challenges – Examines the focus and reach of
top compliance functions. Also looks at the impact and reactions to
some recent regulations. Finally, survey respondents rate the
challenges facing compliance efforts moving forward.
|
More Cutting Edge
Information Reports: |
|
 |
 |
 |